MRC1 and mismatch repair cancer syndrome 1: Although uncommon, MMR deficiency in OCS may represent another opportunity for tumor-agnostic therapy, as there have been two landmark studies showing a remarkable survival benefit using checkpoint inhibition in MMR-deficient endometrial cancer (39, 40).